What is the Aarti Pharmalabs PE ratio today?
Aarti Pharmalabs' PE ratio is 33.3 at the 29 October 2026 close (₹927.65 a share): a market capitalisation of ₹8,412 crore divided by consolidated net profit attributable to shareholders of ₹253 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹173 crore) it is 48.7.
What is the Aarti Pharmalabs net worth?
Aarti Pharmalabs' net worth — shareholders' equity in its consolidated balance sheet — was ₹2,255 crore on 30 September 2026, up 10.2% from ₹2,046 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹8,412 crore at the 29 October 2026 close.
What is the Aarti Pharmalabs book value per share?
Aarti Pharmalabs' book value per share was ₹248.65 on 30 September 2026: shareholders' equity of ₹2,255 crore divided by the 9.07 crore shares in issue, up 10.1% from ₹225.75 a year earlier. The share price at the 29 October 2026 close was ₹927.65.
What is the Aarti Pharmalabs PB ratio (price to book value)?
Aarti Pharmalabs' price-to-book (PB) ratio is 3.73 at the 29 October 2026 close: a market capitalisation of ₹8,412 crore divided by shareholders' equity (book value) of ₹2,255 crore on 30 September 2026. That is a book value of ₹248.65 per share against a share price of ₹927.65.
What is the Aarti Pharmalabs debt to equity ratio?
Aarti Pharmalabs' debt-to-equity ratio was 0.37 on 30 September 2026: borrowings of ₹836 crore against total equity of ₹2,255 crore. A year earlier, on 30 September 2025, it was 0.29.
What is the Aarti Pharmalabs ROE and ROCE?
In FY26, Aarti Pharmalabs' return on equity (ROE) was 8.4% and its return on capital employed (ROCE) was 11.1%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 14.5% and ROCE 18.3%.
What is the Aarti Pharmalabs market cap?
Aarti Pharmalabs' market capitalisation was ₹8,412 crore at the 29 October 2026 close: 9.07 crore shares at ₹927.65 each.
Is Aarti Pharmalabs debt free?
No. Aarti Pharmalabs had borrowings of ₹836 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.37. Its cash and current investments were ₹23.3 crore, so its net debt was ₹813 crore.
What is the Aarti Pharmalabs EPS?
Aarti Pharmalabs' basic earnings per share (EPS) were ₹19.27 in FY26, against ₹30.06 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹28.31.
What is the Aarti Pharmalabs dividend yield?
Aarti Pharmalabs' dividend yield is 0.38% at the 29 October 2026 close: dividends of ₹3.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹927.65. They were ₹2 on 15 September 2026 and ₹1.50 on 16 February 2026 (interim).
What is the Aarti Pharmalabs dividend in 2026 and its record date?
In 2026, Aarti Pharmalabs has declared two dividends totalling ₹3.50 a share: ₹1.50 (interim) with record date 16 February 2026 and ₹2 with record date 15 September 2026.
What is the Aarti Pharmalabs promoter holding?
Promoters held 39.66% of Aarti Pharmalabs on 30 September 2026, down 3.20 percentage points from 42.86% the previous quarter and down 3.22 percentage points from 42.88% a year earlier, according to the shareholding pattern filed with NSE.
What is the Aarti Pharmalabs shareholding pattern?
On 30 September 2026, Aarti Pharmalabs' shares were held by promoters 39.66%, foreign portfolio investors (FII/FPI) 8.15%, domestic institutions (DII) 8.40% (including mutual funds at 0.60%) and retail and other non-institutional investors 43.78%. Over the year, FII holding was up 0.13 percentage points from 8.02% and DII holding was up 1.44 percentage points from 6.96%.
What are the Aarti Pharmalabs latest quarterly results?
Aarti Pharmalabs' latest results are for Q2 FY27 (July–September 2026), filed on 28 October 2026: consolidated net profit attributable to shareholders ₹68.9 crore, up 141.3% from ₹28.6 crore in Q2 FY26; revenue from operations ₹610 crore, up 45.9% year on year.
How does the Aarti Pharmalabs PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Aarti Pharmalabs' PE ratio is 48.7, the second highest of the four: Aarti Drugs 21.0, Advanced Enzyme Tech 17.5 and Dr. Agarwal's Health Care 116.3, a peer average of 51.6. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Aarti Pharmalabs free cash flow?
In FY26, Aarti Pharmalabs generated ₹262 crore of cash from operations and spent ₹409 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹147 crore. In FY25 it was −₹70.5 crore.
What is the Aarti Pharmalabs revenue and profit in FY26?
In FY26 (April 2025–March 2026), Aarti Pharmalabs' consolidated net profit attributable to shareholders was ₹173 crore, down 36.6% from ₹272 crore in FY25, on revenue from operations of ₹1,819 crore (down 14.0%). Over three years, from FY23, net profit was down 10.7%.
When are the Aarti Pharmalabs next results?
Aarti Pharmalabs has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Aarti Pharmalabs compare with its peers?
On FY26 consolidated figures, against Aarti Drugs, Advanced Enzyme Tech and Dr. Agarwal's Health Care: Aarti Pharmalabs' operating margin of 14.6% is the second highest of the four (Aarti Drugs 9.4%, Advanced Enzyme Tech 25.3%, Dr. Agarwal's Health Care 14.1%; peer average 16.3%); its return on equity of 8.4% is the third highest of the four (Aarti Drugs 13.4%, Advanced Enzyme Tech 11.1%, Dr. Agarwal's Health Care 6.8%; peer average 10.4%).
Aarti Pharmalabs vs Aarti Drugs: how do they compare?
In FY26, Aarti Pharmalabs earned net profit attributable to shareholders of ₹173 crore on revenue of ₹1,819 crore, against ₹195 crore on ₹2,565 crore for Aarti Drugs. Aarti Pharmalabs' operating margin was 14.6% (Aarti Drugs 9.4%) and its return on equity 8.4% (Aarti Drugs 13.4%). At the 29 October 2026 close, Aarti Pharmalabs' market capitalisation was ₹8,412 crore against ₹4,098 crore for Aarti Drugs, and its PE ratio on FY26 profit 48.7 against 21.0.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
